<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267525</url>
  </required_header>
  <id_info>
    <org_study_id>0099</org_study_id>
    <nct_id>NCT02267525</nct_id>
  </id_info>
  <brief_title>The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study</brief_title>
  <acronym>DIGEST</acronym>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alfasigma S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Theravance Biopharma R &amp; D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study 0099 explores the efficacy and safety of multiple doses of velusetrag in the treatment
      of symptoms in subjects with diabetic or idiopathic gastroparesis. Three dose levels of
      velusetrag will be evaluated and compared to placebo for approximately 12 weeks of therapy.
      In addition, the study will be used to evaluate the psychometric properties of the
      Gastroparesis Rating Scale (GRS), a daily patient-reported outcome (PRO) measure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day mean GCSI-24H (Gastroparesis Cardinal Symptoms Index) composite score</measure>
    <time_frame>At Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying half-time</measure>
    <time_frame>At Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>103 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">233</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Velusetrag 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Velusetrag 5mg capsules QD (once daily) x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velusetrag 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Velusetrag 15mg capsules QD x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Velusetrag 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Velusetrag 30mg capsules QD x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules QD x 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velusetrag</intervention_name>
    <arm_group_label>Velusetrag 5mg</arm_group_label>
    <arm_group_label>Velusetrag 15mg</arm_group_label>
    <arm_group_label>Velusetrag 30mg</arm_group_label>
    <other_name>TD-5108</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms of gastroparesis (eg, nausea, early satiety, fullness, bloating, upper
             abdominal pain, retching or vomiting) for at least 3 months prior to Screening

          -  Composite score ≥2and &lt;5 on nausea, bloating, feeling excessively full after meals,
             and not able to finish a normal-sized meal items (on the GCSI-2W) at Screening

          -  Delayed gastric emptying by either GES (gastric emptying scintigraphy) or GEBT(gastric
             emptying breath test)

          -  Upper gastrointestinal obstruction ruled out by endoscopy or other imaging (eg,
             computed tomography) after the onset of gastroparesis symptoms

          -  Willing to abstain from prohibited medications, including but not limited to,
             anticholinergics, acetylcholinesterase antagonists, or promotility medications (eg,
             metoclopramide, domperidone, prucalopride, erythromycin) for: 24 hours prior to
             gastric emptying test during Screening, if applicable; 24 hours prior to start of the
             Baseline period; and during the Baseline Period

          -  GCSI-24H 7-day mean composite score ≥2.5 and &lt;5 at Day 1

        Exclusion Criteria:

          -  If Type 1 or Type 2 diabetic, a glycosylated hemoglobin (HbA1c) level &gt;11%

          -  Prior history of gastric surgery, including but not limited to gastrectomy, gastric
             bypass, gastric banding, pyloroplasty, vagotomy, or fundoplication, which has
             manipulated the natural anatomy of the stomach

          -  History of intrapyloric botulinum toxin injection within 3 months of Screening or
             currently has functioning implantable electric stimulator

          -  History of alcohol or drug abuse or dependence within the last year prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deanna Nguyen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <disposition_first_submitted>April 13, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 13, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 17, 2018</disposition_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroparesis</keyword>
  <keyword>Diabetic</keyword>
  <keyword>Idiopathic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

